Details

Autor(en) / Beteiligte

• Jaroszewicz, Jerzy
• Kowalska, Justyna
• Pawłowska, Małgorzata
• Rogalska, Magdalena
• Zarębska-Michaluk, Dorota
• Rorat, Marta
• Lorenc, Beata
• Czupryna, Piotr
• Sikorska, Katarzyna
• Piekarska, Anna
• Dworzańska, Anna
• Zaleska, Izabela
• Mazur, Włodzimierz
• Kozielewicz, Dorota
• Kłos, Krzysztof
• Podlasin, Regina
• Angielski, Grzegorz
• Oczko-Grzesik, Barbara
• Figlerowicz, Magdalena
• Szetela, Bartosz
• Bolewska, Beata
• Frańczak-Chmura, Paulina
• Flisiak, Robert
• Tomasiewicz, Krzysztof

Titel

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy

Ist Teil von

• Cancers, 2022-09, Vol.14 (19), p.4720

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB*

Beschreibungen/Notizen

• Data on the use of remdesivir, the first antiviral agent against SARS-CoV-2, are limited in oncologic patients. We aimed to analyze contributing factors for mortality in patients with malignancies in the real-world CSOVID-19 study. In total, 222 patients with active oncological disorders were selected from a nationwide COVID-19 study of 4890 subjects. The main endpoint of the current study was the 28-day in-hospital mortality. Approximately half of the patients were male, and the majority had multimorbidity (69.8%), with a median age of 70 years. Baseline SpO2 < 85% was observed in 25%. Overall, 59 (26.6%) patients died before day 28 of hospitalization: 29% due to hematological, and 20% due to other forms of cancers. The only factor increasing the odds of death in the multivariable model was eGFR < 60 mL/min/m2 (4.621, p = 0.02), whereas SpO2 decreased the odds of death at baseline (0.479 per 5%, p = 0.002) and the use of remdesivir (0.425, p = 0.03). This study shows that patients with COVID-19 and malignancy benefit from early remdesivir therapy, resulting in a decrease in early mortality by 80%. The prognosis was worsened by low glomerular filtration rate and low peripheral oxygen saturation at baseline underlying the role of kidney protection and early hospitalization.